# HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

> **NCT03500991** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 10 (actual)

## Conditions studied

- Central Nervous System Tumor, Pediatric
- Glioma
- Ependymoma
- Medulloblastoma
- Germ Cell Tumor
- Atypical Teratoid/Rhabdoid Tumor
- Primitive Neuroectodermal Tumor
- Choroid Plexus Carcinoma
- Pineoblastoma

## Interventions

- **BIOLOGICAL:** HER2-specific chimeric antigen receptor (CAR) T cell

## Key facts

- **NCT ID:** NCT03500991
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-26
- **Primary completion:** 2024-01-17
- **Final completion:** 2039-07-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500991, "HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03500991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*